Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300817 · ClinicalTrials.gov registry record · Phase 1
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer
A Phase 1 study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT03300817: Active Phase 1 study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).
NCT03300817 is a Phase 1 study of Lung Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 5,042-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03300817, a Phase 1 study of Lung Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL MUC1 Peptide-Poly-ICLC Vaccine
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03300817
The ClinicalTrials.gov registry entry for NCT03300817 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,042-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03300817 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03300817 about?
NCT03300817 is a clinical study titled "MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer". This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-...
What is the current status of trial NCT03300817?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2017-12-27. Estimated completion is 2025-12-01.
What conditions does trial NCT03300817 study?
This clinical trial studies the following conditions: Lung Carcinoma.
What interventions are being tested in trial NCT03300817?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), MUC1 Peptide-Poly-ICLC Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03300817?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03300817 being conducted?
This trial has 2 study locations across Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
RECRUITING · Phase 1
-
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
ACTIVE NOT RECRUITING · Phase 1
-
Iloprost in Preventing Lung Cancer in Former Smokers
COMPLETED · Phase 1
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
The Rise in Robotic Atypical Segmentectomies
RECRUITING
-
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.